Inpixon Reports First Quarter 2023 Financial Results and Provides Business Update
- Inpixon achieved a 17% increase in revenue to $3.1 million for Q1 2023 compared to the same period last year
- Gross profit for Q1 2023 was $2.3 million, representing a 25% increase compared to the same period last year
- The gross profit margin for Q1 2023 was 75%, a 5% increase compared to Q1 2022
- Net loss from continuing operations for Q1 2023 was $12.3 million, an increase of approximately $1.5 million compared to the same period last year
- Non-GAAP Adjusted EBITDA for Q1 2023 was a loss of $7.7 million, a decrease compared to the prior year period
Completed the Spin-off of Workplace Experience Business Line on March 14
Conference Call to be Held Today at 4:30 p.m. Eastern Time
"The spinoff of the workplace experience business line was our most significant accomplishment in the first quarter of this year," commented Nadir Ali, CEO of Inpixon. "This transaction was a key focus for the company throughout the last several months and demonstrates our commitment to increasing value for shareholders. At the same time, for the remainder of our business, we were also able to achieve a
"Overall, we have maintained a solid balance sheet with over
Financial Results
Revenues for the three months ended March 31, 2023 were
Non-GAAP Adjusted EBITDA for the three months ended March 31, 2023, was a loss of
Proforma non-GAAP net loss per basic and diluted common share for the three months ended March 31, 2023, was a loss of
In accordance with applicable accounting guidance, the results of the workplace experience business line are presented as discontinued operations in the Consolidated Statements of Income and, as such, have been excluded from both continuing operations and segment results for all periods presented prior to the completion of the CXApp Spin-off. The Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. Please refer to the quarterly report on Form 10-Q for the quarterly period ended March 31, 2023 to be filed with the SEC for additional information.
Conference Call
Inpixon management will host a conference call today at 4:30 p.m. Eastern Time to discuss the company's financial results for the first quarter of 2023 ended March 31, 2023, as well as provide an update on the company's corporate progress and other developments.
The conference call will be available via telephone by dialing toll-free 888-506-0062 for
Investors and other interested parties are invited to submit questions to management prior to the call's start via email to inpx@crescendo-ir.com.
A webcast replay will be available on the company's Investor Relations section of the website (ir.inpixon.com/ir-news-events/ir-calendar) through May 15, 2024. A telephone replay of the call will be available approximately one hour following the call, through May 22, 2023, and can be accessed by dialing 877-481-4010 for
About Inpixon
Inpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence®, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company's Indoor Intelligence and industrial real-time location system (RTLS) solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, analytics, sensor fusion, IIoT and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, and Twitter, and visit inpixon.com.
Safe Harbor Statement
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19, global conflicts, inflation and other global events on Inpixon's results of operations and global supply chain constraints, the anticipated benefits of the spin-off of the Workplace Experience business line may not be achieved, Inpixon's ability to integrate the products and business from acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon's technology, Inpixon's ability to maintain compliance with Nasdaq's continued listing requirements, the ability to obtain financing if needed, competition, general economic conditions and other factors that are detailed in Inpixon's periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.
Non-GAAP Financial Measures
Management believes that certain financial measures not in accordance with generally accepted accounting principles in
Management provides Adjusted EBITDA and pro forma net loss per share measures so that investors will have the same financial information that management uses, which may assist investors in assessing Inpixon's performance on a period-over-period basis. Adjusted EBITDA or pro forma net loss per share is not a measure of financial performance under GAAP, and should not be considered an alternative to net income (loss) or any other measure of performance under GAAP, or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA and pro forma net loss per share have limitations as analytical tools and should not be considered either in isolation or as a substitute for analysis of Inpixon's results as reported under GAAP.
For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the "Reconciliation of Non-GAAP Financial Measures" table accompanying this press release.
Contacts
General inquiries:
Inpixon
Email: marketing@inpixon.com
Web: inpixon.com/contact-us
Investor relations:
Crescendo Communications for Inpixon
Tel: +1 212-671-1020
Email: INPX@crescendo-ir.com
INPIXON AND SUBSIDIARIES | |||||
CONSOLIDATED BALANCE SHEETS | |||||
(In thousands, except number of shares and par value data) | |||||
As of | |||||
March 31, 2023 | December 31, | ||||
ASSETS | |||||
Current Assets | |||||
Cash and cash equivalents | $ | 15,254 | $ | 10,235 | |
Accounts receivable, net of allowances of | 2,999 | 1,889 | |||
Notes and other receivables | 430 | 86 | |||
Inventory | 2,179 | 2,442 | |||
Note receivable | -- | 150 | |||
Prepaid assets and other current assets | 2,797 | 2,803 | |||
Current assets of discontinuted operations | -- | 12,261 | |||
Total Current Assets | 23,659 | 29,866 | |||
Property and equipment, net | 1,052 | 1,064 | |||
Operating lease right-of-use asset, net | 484 | 531 | |||
Software development costs, net | 1,313 | 1,265 | |||
Investment in equity securities | 364 | 330 | |||
Long-term investments | 50 | 716 | |||
Intangible assets, net | 2,810 | 2,994 | |||
Other assets | 175 | 158 | |||
Non-current assets of discontinued operations | -- | 20,711 | |||
Total Assets | $ | 29,907 | $ | 57,635 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
Current Liabilities | |||||
Accounts payable | $ | 1,767 | $ | 1,503 | |
Accrued liabilities | 5,112 | 2,619 | |||
Operating lease obligation, current | 199 | 211 | |||
Deferred revenue | 1,382 | 1,323 | |||
Short-term debt | 14,971 | 13,643 | |||
Acquisition liability | -- | 197 | |||
Current liabilities of deconsolidated operations | -- | 5,218 | |||
Total Current Liabilities | 23,431 | 24,714 | |||
Long Term Liabilities | |||||
Operating lease obligations, noncurrent | 297 | 334 | |||
Non-current liabilities of deconsolidated operations | -- | 472 | |||
Total Liabilities | 23,728 | 25,520 | |||
Commitments and Contingencies | -- | -- | |||
Stockholders' Equity | |||||
Preferred Stock - | |||||
Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of March 31, 2023 and December 31, 2022, respectively; | -- | -- | |||
Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of March 31, 2023 and December 31, 2022, respectively. | -- | -- | |||
Common Stock - | 16 | 4 | |||
Additional paid-in capital | 339,148 | 346,668 | |||
Treasury stock, at cost, 1 share | (695) | (695) | |||
Accumulated other comprehensive (loss) income | (198) | 1,061 | |||
Accumulated deficit | (330,586) | (313,739) | |||
Stockholders' Equity Attributable to Inpixon | 7,685 | 33,299 | |||
Non-controlling interest | (1,506) | (1,184) | |||
Total Stockholders' Equity | 6,179 | 32,115 | |||
Total Liabilities and Stockholders' Equity | $ | 29,907 | $ | 57,635 |
INPIXON AND SUBSIDIARIES | |||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||
(In thousands, except share and per share data) | |||||
For the Three Months Ended | |||||
March 31, | |||||
2023 | 2022 | ||||
Revenues | $ | 3,104 | $ | 2,649 | |
Cost of Revenues | 791 | 797 | |||
Gross Profit | 2,313 | 1,852 | |||
Operating Expenses | |||||
Research and development | 1,983 | 2,124 | |||
Sales and marketing | 1,115 | 1,169 | |||
General and administrative | 5,613 | 7,334 | |||
Acquisition related costs | 164 | 115 | |||
Transaction costs | 1,400 | -- | |||
Amortization of intangibles | 220 | 347 | |||
Total Operating Expenses | 10,495 | 11,089 | |||
Loss from Operations | (8,182) | (9,237) | |||
Other (Expense) Income | |||||
Interest (expense)/ income, net | (1,725) | 1 | |||
Other income/(expense), net | 29 | (44) | |||
Unrealized gain/(loss) on equity securities | 34 | (1,503) | |||
Total Other Expense | (1,662) | (1,546) | |||
Net Loss from Continuing Operations, before tax | (9,844) | (10,783) | |||
Income tax provision | (2,478) | -- | |||
Net Loss from Continuing Operations | (12,322) | (10,783) | |||
Loss from Discontinued Operations, Net of Tax | (4,856) | (774) | |||
Net Loss | (17,178) | (11,557) | |||
Net Loss Attributable to Non-controlling Interest | (305) | (346) | |||
Net Loss Attributable to Stockholders of Inpixon | $ | (16,873) | $ | (11,211) | |
Accretion of Series 7 preferred stock | -- | (4,555) | |||
Accretion of Series 8 Preferred Stock | -- | (548) | |||
Deemed dividend for the modification related to Series 8 Preferred Stock | -- | (2,627) | |||
Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred Stock | -- | 1,469 | |||
Amortization premium- modification related to Series 8 Prefered Stock | -- | 110 | |||
Net Loss Attributable to Common Stockholders | $ | (16,873) | $ | (17,362) | |
Net Loss Per Share - Basic and Diluted | $ | (1.38) | $ | (9.05) | |
Weighted Average Shares Outstanding | |||||
Basic and Diluted | 12,238,684 | 1,917,629 | |||
Comprehensive Loss | |||||
Net Loss | $ | (17,178) | $ | (11,557) | |
Unrealized foreign exchange loss from cumulative translation adjustments | (1,259) | (102) | |||
Comprehensive Loss | $ | (18,437) | $ | (11,659) |
INPIXON AND SUBSIDIARIES | |||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||
(In thousands) | |||||
For the Three Months Ended | |||||
March 31, | |||||
2023 | 2022 | ||||
Cash Flows Used In Operating Activities | |||||
Net loss | $ | (17,178) | $ | (11,557) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Depreciation and amortization | 429 | 317 | |||
Amortization of intangible assets | 1,025 | 1,489 | |||
Amortization of right of use asset | 110 | 169 | |||
Stock based compensation | 329 | 1,533 | |||
Earnout expense valuation benefit | -- | (2,827) | |||
Amortization of debt discount | 834 | -- | |||
Unrealized loss on foreign currency transactions | (205) | (167) | |||
Distribution of equity method investment shares to employees as compensation | 666 | -- | |||
Deferred income tax | 2,478 | -- | |||
Unrealized loss on equity securities | (34) | 1,503 | |||
Other | -- | 146 | |||
Changes in operating assets and liabilities: | |||||
Accounts receivable and other receivables | (1,994) | (239) | |||
Inventory | 283 | 181 | |||
Prepaid expenses and other current assets | 274 | (3,607) | |||
Other assets | (4) | 41 | |||
Accounts payable | (534) | (1,345) | |||
Accrued liabilities | 3,545 | (109) | |||
Income tax liabilities | (2) | (40) | |||
Deferred revenue | 584 | (666) | |||
Operating lease obligation | (109) | (141) | |||
Net Cash Used in Operating Activities | $ | (9,503) | $ | (15,319) | |
Cash Flows Used in Investing Activities | |||||
Purchase of property and equipment | (6) | (81) | |||
Investment in capitalized software | (220) | (107) | |||
Sales of treasury bills | -- | 28,001 | |||
Proceeds from repayment of note receivable | 150 | -- | |||
Issuance of note receivable | (300) | -- | |||
Net Cash (Used in) Provided By Investing Activities | $ | (376) | $ | 27,813 | |
Cash From Financing Activities | |||||
Net proceeds from issuance of preferred stock and warrants | $ | -- | $ | 46,906 | |
Net proceeds from promissory note | 125 | -- | |||
Net proceeds for registered direct offering | 14,966 | -- | |||
Cash paid for redemption of preferred stock series 7 | -- | (49,250) | |||
Taxes paid related to net share settlement of restricted stock units | -- | (336) | |||
Net proceeds from promissory notes | -- | 364 | |||
Repayment of CXApp acquisition liability | (197) | (1,787) | |||
Common shares issued for net proceeds from warrants | 1 | -- | |||
Distribution to shareholders related to spin-off of CXApp | (10,003) | -- | |||
Net Cash Provided By (Used in) Financing Activities | $ | 4,892 | $ | (4,103) | |
Effect of Foreign Exchange Rate on Changes on Cash | 6 | (19) | |||
Net (Decrease) Increase in Cash and Cash Equivalents | (4,981) | 8,372 | |||
Cash and Cash Equivalents - Beginning of year | 20,235 | 52,480 | |||
Cash and Cash Equivalents - End of year | $ | 15,254 | $ | 60,852 |
Reconciliation of Non-GAAP Financial Measures: | |||
For the 3 Months Ended | |||
(In thousands) | March 31, | ||
2023 | 2022 | ||
Net loss attributable to common stockholders | $ (16,873) | $ (17,362) | |
Interest expense/(income), net | 1,724 | (2) | |
Income tax provision | 2,478 | 100 | |
Depreciation and amortization | 1,454 | 1,806 | |
EBITDA | (11,217) | (15,458) | |
Adjusted for: | |||
Non-recurring one-time charges: | |||
Unrealized (gain)/loss on equity securities | (34) | 1,503 | |
Acquisition transaction/financing costs | 164 | 121 | |
Earnout compensation benefit | - | (2,827) | |
Professional service fees | - | 8 | |
Transaction costs | 2,443 | - | |
Accretion of series 7 preferred stock | - | 4,555 | |
Accretion of series 8 preferred stock | - | 548 | |
Deemed dividend modification Series 8 preferred stock | - | 2,627 | |
Deemed contribution for the modication related to warrants issued in connection with the Series 8 Preferred Stock | - | (1,469) | |
Amortization premium - modification to Series 8 preferred stock | - | (110) | |
Distribution of equity method investment shares to employees as compensation | 666 | - | |
Unrealized foreign exchange (gains)/losses | (205) | 89 | |
Stock-based compensation – compensation and related benefits | 329 | 1,533 | |
Severance costs | 127 | 111 | |
Adjusted EBITDA | $ (7,727) | $ (8,769) | |
For the 3 Months Ended | |||
(In thousands, except share data) | March 31, | ||
2023 | 2022 | ||
Net loss attributable to common stockholders | $ (16,873) | $ (17,362) | |
Adjustments: | |||
Non-recurring one-time charges: | |||
Unrealized (gain)/loss on equity securities | (34) | 1,503 | |
Acquisition transaction/financing costs | 164 | 121 | |
Earnout compensation benefit | - | (2,827) | |
Professional service fees | - | 8 | |
Transaction costs | 2,443 | - | |
Accretion of series 7 preferred stock | - | 4,555 | |
Accretion of series 8 preferred stock | - | 548 | |
Deemed dividend modification Series 8 preferred stock | - | 2,627 | |
Deemed contribution for the modication related to warrants issued in connection with the Series 8 Preferred Stock | - | (1,469) | |
Amortization premium - modification to Series 8 preferred stock | - | (110) | |
Distribution of equity method investment shares to employees as compensation | 666 | - | |
Unrealized foreign exchange (gains)/losses | (205) | 89 | |
Stock-based compensation – compensation and related benefits | 329 | 1,533 | |
Severance costs | 127 | 111 | |
Amortization of intangibles | 1,025 | 1,489 | |
Proforma non-GAAP net loss | $ (12,358) | $ (9,184) | |
Proforma non-GAAP net loss per basic and diluted common share | $ (1.01) | $ (4.79) | |
Weighted average basic and diluted common shares outstanding | 12,238,684 | 1,917,629 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/inpixon-reports-first-quarter-2023-financial-results-and-provides-business-update-301825058.html
SOURCE Inpixon
FAQ
What was Inpixon's revenue for Q1 2023?
What was Inpixon's gross profit margin for Q1 2023?
What was Inpixon's net loss from continuing operations for Q1 2023?